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Summary
The Hyper-immunoglobulin M syndromes (HIGM) are a
heterogeneous group of genetic disorders resulting in defects of
immunoglobulin class switch recombination (CSR), with or
without defects of somatic hypermutation (SHM). They can be
classiﬁed as defects of signalling through CD40 causing both a
humoral immunodeﬁciency and a susceptibility to opportu-
nistic infections, or intrinsic defects in B cells of the
mechanism of CSR resulting in a pure humoral immunode-
ﬁciency. A HIGM picture can also be seen as part of
generalized defects of DNA repair and in antibody deﬁciency
syndromes, such as common variable immunodeﬁciency.
CD40 signalling defects may require corrective therapy with
bone marrow transplantation. Gene therapy, a potential
curative approach in the future, currently remains a distant
prospect. Those with a defective CSR mechanism generally do
well on immunologoblulin replacement therapy. Complica-
tions may include autoimmunity, lymphoid hyperplasia and,
in some cases, a predisposition to lymphoid malignancy.
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The Hyper-immunoglobulin M (HIGM) syndromes are a
group of primary immunodeﬁciency disorders in which
defective immunoglobulin (Ig) class switch recombination
(CSR) leads to deﬁciency of IgG, IgA and IgE with preserved
or elevated levels of IgM. A number of different gene
products are involved in this process and defects of a
number of these have now been described (Lee et al, 2005).
Studies of patients affected by these conditions have helped
elucidate the process of CSR and the related process of
somatic hypermutation (SHM). Most, but not all, patients
with CSR defects also show defective SHM. The genetic
disorders can be broadly classiﬁed into defects restricted to B
cells and defects that additionally affect the functions of
other cells, including monocytes, macrophages and dendritic
cells, whose function requires signalling through the CD40
receptor. The former cause a pure humoral immunodeﬁ-
ciency while the latter are associated with an additional
defect of cell-mediated immunity and a consequent suscep-
tibility to opportunistic infections.
In addition to the classical forms of HIGM, other more
complex defects of the DNA repair mechanism can also lead to
a HIGM-like immunological pattern as part of a more
generalized disorder. Additionally, other antibody deﬁciency
disorders, such as common variable immunodeﬁciency
(CVID) or occasionally X-linked agammaglobulinaemia, can
present with a picture of low IgG and IgA with preserved IgM
thus mimicking HIGM.
A secondary HIGM pattern of immunodeﬁciency can be
seen with congenital rubella infection, malignancy or in
patients on antiepileptic medication. This review will not
address these forms of the disorder.
An understanding of the details of B cell development and
the generation of diverse antibodies of different isotypes is
helpful in explaining the different causes of HIGM and will be
described here.
B cell development
Maturation from the common lymphoid precursor to a class-
switched immunoglobulin-producing B cell or a terminally
differentiated plasma cell involves antigen-independent and
-dependent phases (Fig 1). This has been described in previous
reviews (Ghia et al, 1998; LeBien, 1998). The antigen-inde-
pendent phase occurs in the liver during fetal life and
thereafter in the bone marrow. IG gene rearrangement of the
germline DNA to produce unique antibody speciﬁcities
commences at the pro (precursor)- B cell stage and is
completed in the pre- B cell stage. The process of Ig gene
rearrangement is initiated by the recombination activating
genes (RAG1 and RAG2), which bind to speciﬁc recombina-
tion signal sequences to initiate double stranded (ds) DNA
breaks. There is excision of intervening DNA to bring the
required genes into juxtaposition followed by dsDNA repair
using the non homologous end-joining (NHEJ) apparatus.
Genetic defects in RAG genes or in the genes encoding proteins
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Artemis or Ligase IV) result in a failure to generate T and B cell
receptors and a clinical picture of severe combined immuno-
deﬁciency rather than HIGM (de Villartay, 2009). Exceptions
to this are Ataxia–telangiectasia and Nijmegen breakage
syndrome, both affecting NHEJ, and sometimes resulting in
a HIGM picture (see below).
Immunoglobulin heavy chain gene (IGH) rearrangement
always results initially in the association of VDJ sequences with
the l chain constant region gene, IGHM. Mature naı ¨ve B cells
express surface IgM and IgD.
Class switch recombination
The second antigen-dependent stage of B cell development
occurs in the periphery and is continued in the germinal
centres of lymphoid tissue (MacLennan, 1994; Rajewsky,
1996). This stage is dependent on a number of signals
including antigen engagement of the B cell receptor and
co-stimulatory signals through the effects of cytokines and
direct interaction with T cells. B cells may progress to
become plasma cells or follow a route of germinal centre
maturation (including CSR) to become memory B cells
which express CD27. CD40Ligand/CD40 interaction pro-
motes germinal centre development of B cells and is an
absolute requirement for the initiation of CSR and SHM.
This process is illustrated in Fig 2. CD40 is a member of the
tumour necrosis factor (TNF) receptor family expressed
constitutively on the B cell surface while CD40 ligand (or
CD154) is a member of the TNF family, which is transiently
expressed on activated CD4-positive T lymphocytes during
the immune response. Signalling through CD40 occurs
through activation of a family of TNF receptor associated
factors (TRAFs) and thence via nuclear factor kappa B
(NFjB) signalling to the nucleus.
CSR involves relocating the previously constructed unique
V(D)J combination from its association with the constant
region gene IGHM of IgM to an alternative constant region
gene, one of the IGHG genes for IgG, IGHGA gene for IgA or
IGHE for IgE (Coffman et al, 1993). The process, illustrated in
Figs 3 and 4, involves the creation of dsDNA breaks, excision
of the intervening sequences and then dsDNA repair. This
process is distinct from that involved in immunoglobulin gene
(VDJ) rearrangement. Recombination occurs between switch
(S) regions that are found ﬂanking each constant region gene
at the 5¢ end and in the intron between the VDJ and IGHM
sequences. The process is initiated by DNA transcription at a
point upstream from the S regions. This creates single strand
DNA substrates for the enzyme activation induced cytidine
deaminase (AID). Through a process of deamination, AID is
able to convert cytidine into uracil residues (Bransteitter et al,
2003). The enzyme uracil N glycosylase (UNG) excises the
uracil residues facilitating the production of a single-stranded
break in the DNA strand by an endonuclease (Rada et al,
2002). The mismatch repair (MMR) complex of proteins,
including the PMS2 (postmeiotic segregation increased 2)
protein, has a probable role in converting single stranded into
double strand DNA breaks (Schrader et al, 2007; Stavnezer
et al, 2008) as does the MRE11-RAD50-NBS1(MRN) complex
(Larson et al, 2005). Following excision of the intervening
DNA, repair of the dsDNA is initiated. Ataxia-telangiectasia
mutated (ATM) protein kinase is involved in this process
(Reina-San-Martin et al, 2004) and DNA repair employs the
NHEJ machinery (Kotnis et al, 2009).
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Fig 1. Stages of B cell development. CLP, Common Lymphoid Precursor; Pro B E/M/L, Precursor B cell early/mid/late; B Mem, Memory B cell;
CSR, Class switch recombination.
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The process of SHM is also initiated by the action of AID
(Fig 3). SHM results in the generation of very frequent
mutations in the IGHV genes. B cells expressing those mutated
IGHV genes that have higher antibody afﬁnity are preferentially
selected to proliferate in germinal centres in the presence of
antigen loaded follicular dendritic cells and follicular B helper T
cellsthusachievingafﬁnitymaturationoftheantibodyresponse
(Vinuesa et al, 2005). The process of SHM is less well
understood than CSR. AID function is critical and dsDNA
breaks occur as in CSR. The mismatched repair enzymes and
error – prone DNA polymerases are employed to achieve repair
with ahighrate ofbasesubstitutions buttheNHEJmachinery is
not involved (Schrader et al, 1999; Poltoratsky et al, 2000).
Table I lists the primary genetic disorders causing HIGM
syndrome. Although others have classiﬁed Hyper IgM syn-
dromes into Types 1–6, this is not helpful in terms of
functional consequences and, though deﬁned in Table I, the
classiﬁcation will not be used in this review.
The relative frequencies of the different causes of HIGM
have been reported in a group of 140 patients (130 males) with
a susceptibility to infections associated with deﬁciency of IgG
and IgA in combination with normal or elevated circulating
CD40L 
CTK
P
CSS
CD40
CD4
T cell 
B cell 
TRAFS
NF B
I B
I
DNA 
Fig 2. B cell activation to induce CSR. CTK, Cytokines; CSS, Co-stimulatory signals; TRAFS, Tumour necrosis factor receptor (family) associated
factors; Ijj,I jB kinase complex; P, phosphate. IjB(a) inhibitory protein is normally complexed with NFjB, nuclear factor jB, but upon
phosphorylation by Ijj dissociates allowing NFjB to translocate to the nucleus.
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Fig 3. Class switch recombination to generate an IgG1 isotype immunoglobulin. (1) Following initiation of transcription, activation-induced cytidine
deaminase (AID) is able to bind to Switch (S) regions and Variable (IGHV) genes to initiate class switch recombination and somatic hypermutation.
M, D, G1, G2A etc. represent constant region heavy chain genes IGHM…., etc. S-M,S - G1 etc. represent switch regions of IGH heavy chain genes
IGHM, IGHG2 etc. (2) dsDNA breaks induced in switch regions (see Fig 4). (3) Intervening DNA between switch l region and target heavy chain
constant region switch region (in this case IGHG1) is excised. (4) dsDNA repair brings IGHG1 adjacent to VDJ region. (2a and 4a) Mismatch repair
enzymes and error prone DNA polymerases create frequent base substitutions in the IGHV genes to create a hypermutated VDJ region VDJ*.
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extensive genetic testing. By far the commonest defect found,
accounting for 98 (70%) of cases, was X-linked HIGM caused
by mutations in the gene encoding CD40 ligand (CD40LG).
Other identiﬁed defects affected AID in 4 (3%), UNG and
NFjB in one case each and Bruton tyrosine kinase (the cause of
X-linked agammaglobulinaemia) in 3 (2%) cases. No muta-
tions were identiﬁed in the CD40 gene, in SH2D1A (a gene
associated with X linked lymphoproliferative disease) or in
ICOS (a gene associated with a rare form of CVID). The thirty-
three (24%) patients who did not have identiﬁed mutations
were thought to include molecularly undeﬁned cases of CVID.
Other genes now known to be associated with CVID (see
below) were not examined in this study.
HIGM as part of a combined immunodeﬁciency
Defects of signalling through the CD40 receptor affect more
than just B cell function, because CD40 is also expressed on
macrophages/monocytes and dendritic cells and lack of
signalling to such cells results in impaired handling of
opportunistic pathogens. CD40 is also expressed on platelets
and, in the presence of inﬂammation, on endothelial and
epithelial cells. The pathway is involved in platelet activation
(Inwald et al, 2003) and there is increasing evidence for its role
in the generation of atheroclerosis (Engel et al, 2009). Clinical
problems related to defective signalling in non-immunological
cells have not been described.
CD40 ligand deﬁciency
The ﬁrst recognized and by far the commonest form of HIGM
Syndrome, accounting for at least 70% of patients with CSR
Table I. Genetically deﬁned types of HIGM syndrome.
Defect Inheritance Infection susceptibility
Lymphoid
Hypertrophy Autoimmunity Lymphoma
CSR
defect
SHM
defect
DNA
Repair
defect
XHIM-CD40 L deﬁciency
(Type 1 HIGM)
XL Bacterial, opportunistic ) Yes No Yes Yes No
CD40 defect (Type 3 HIGM) AR Bacterial, opportunistic ) Yes No Yes Yes No
NFjB signalling defects
(Type 6 HIGM)
XL/AD Bacterial, opportunistic ) Yes No Yes Yes No
AID deﬁciency (Type 2 HIGM) AR Bacterial ++ Yes No Yes Yes No
AID C terminal defect AD Bacterial + ? No Yes No No
UNG deﬁciency (Type 5 HIGM) AR Bacterial + ? Probable Yes No No
PMS2 deﬁciency AR Bacterial ? ? ? Yes No No
Complex disorders affecting NHEJ
DNA repair (Ataxia-Telangiectasia,
Nijmegen breakage syndrome)
AR Mainly bacterial some
opportunistic
) Yes Yes Yes No Yes
XL, X linked; AR, autosomal recessive; AD, autosomal dominant. AID, activation-induced cytidine deaminase; UNG, uracil N glycosylase; PMS2,
postmeiotic segregation increased 2; NHEJ, non-homologous end joining.
Type 4 HIGM refers to a genetically undeﬁned type.
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Fig 4. Development of dsDNA breaks in switch regions as part CSR.
(1) Transcription is initiated upstream from the IGHM switch region
(S-IGHM). (2) Single strands of DNA available for action of Acti-
vation-Induced Cytidine deaminase (AID). RNA-P (ribonucleic acid
polymerase) is shown associated with the template strand. (3)
Cytidine (C) residues deaminated to uracil (U) by AID. Uracil N
Glycosylase (UNG) excises uracil residues. (4) Apurinic/apyridinic
endonuclease 1 (APE-1) creates multiple ‘nicks’ in non template DNA
strand and a single nick is made in the opposing strand. (5) Mismatch
Repair (MMR) enzymes convert single strand ‘nicks’ to a dsDNA
break.
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ligand (CD40LG) (Korthauer et al, 1993). CD40 ligand is a
39 kD glycoprotein that is a member of the TNF family. The
gene, at chromosome Xq26, encodes the molecule expressed in
trimeric form on the cell surface and comprises a CD40 binding
domain on the cell surface, a short transmembrane domain and
a cytoplasmic tail. Occasional symptomatic female carriers with
skewed lyonization have been reported (de Saint Basile et al,
1999; Imai et al, 2006). Expression of the molecule is very
tightly regulated occurring only transiently upon activation of
CD4+ve T lymphocytes. Testing for expression of the molecule
involves overnight activation of T-cells, typically with phyto-
haemagglutinin and phorbol myristate acetate followed by ﬂow
cytometric analysis. It is important to look for other markers of
T-cell activation, such as CD25 or CD69 expression, as controls
for the activation process (Gilmour et al, 2003). This will
conﬁrm the diagnosis in the majority of cases in whom
mutations result in a lack of protein expression on the cell
surface. In a minority of cases with splice site (Seyama et al,
1998a) or cytoplasmic tail mutations (Yong et al, 2008a) some,
or even normal, surface expression is seen making the diagnosis
more difﬁcult to conﬁrm. In the neonatal period immaturity in
T-cell responses results in failure of expression of this molecule
using standard T-cell activation stimuli. Except in rare cases
with some protein expression, there is severely impaired
production of IgG and IgA. Around half of the patients have
elevated levels of IgM at presentation, the remainder having
levels within the normal range (Levy et al, 1997). The humoral
immunodeﬁciency results in susceptibility to bacterial infec-
tions particularly affecting the respiratory tract. There is no
response to protein antigens, though some IgM anti-polysac-
charide antibodies, including isohemagglutinins, can be pro-
duced. Memory (CD27+ve) B-cells are either absent or present
in only very reduced numbers (Agematsu et al, 1998).
A second consequence of a lack of CD40 ligand expression
involves T-cell interaction with macrophages/monocytes.
Expression of CD40 on activated monocytes normally results
in interaction with activated CD4 cells expressing CD40 ligand
to facilitate the production of T-helper cell type 1 (TH1)
cytokines (DeKruyff et al, 1997), including interleukin-12 and
interferon-gamma, which are important in the normal
handling of opportunistic intracellular pathogens including
Pneumocystis jiroveci (Levy et al, 1997; Winkelstein et al, 2003),
Cryptosporidium species (Hayward et al, 1997), Toxoplasma
gondii (Subauste et al, 1999) and Mycobacteria species
(Hayashi et al, 1999). In the case of Cryptosporidium species
it has been shown that ligation of CD40 expressed on inﬂamed
biliary epithelium, using soluble CD40L, has a direct effect in
killing the organism even in the absence of effector T-cells
(Hayward et al, 1997).
CD40 deﬁciency
This syndrome, a rare cause of HIGM, has been described in
patients presenting a very similar clinical picture to boys with
X-linked HIGM Syndrome caused by CD40 Ligand deﬁciency
(Ferrari et al, 2001; Lougaris et al, 2005). Flow cytometric
analysis of CD40 expression on B cells and mutation analysis
can be used to conﬁrm the diagnosis.
HIGM syndrome associated with ectodermal
dysplasia and immunodeﬁciency
Signalling through CD40 on B-cells involves NFjB. Boys with
X-linked anhidrotic ectodermal dysplasia and immunodeﬁ-
ciency have hypomorphic mutations in the IKBKG gene,
coding for a protein IKK – gamma part of a kinase complex
involved in releasing NFjB from its association with the
inhibitory complex IjB allowing translocation to the nucleus.
(Zonana et al, 2000; Dofﬁnger et al, 2001). An overlapping
clinical syndrome with autosomal dominant inheritance
causing ectodermal dysplasia and immunodeﬁciency is caused
by mutations in NFKBIA encoding IjBa, part of the inhibitory
complex (Courtois et al, 2003). Both these syndromes are very
variable both in immunological and non-immunological
features. A HIGM pattern of immunodeﬁciency can be seen
with some mutations (Jain et al, 2001; Orange et al, 2005).
Given that NF jB is involved in a number of T-cell and Toll
receptor signalling pathways the immunodeﬁciency is more
extensive than simply a class switch defect. Patients are
therefore prone to a variety of bacterial and opportunistic
infections. The non-haemopoeitic features of the syndrome
reﬂect the usage of NFjB signalling by other cell lineages.
Clinical complications
Most of the experience with these disorders is from CD40
Ligand deﬁciency (Levy et al, 1997; Winkelstein et al, 2003) as
the number of reported cases with the other two disorders is
too small to allow ﬁrm conclusions. Clinical problems occur
early in life with a median age at diagnosis of <12 months.
Bacterial infections. Recurrent sinopulmonary infections are a
consequence of the humoral immunodeﬁciency in this
syndrome. The picture is similar to that seen in other forms
of humoral immunodeﬁciency with recurrent respiratory tract
infections potentially leading to bronchiectasis, sinus infections
and ear infections. Treatment with immunoglobulin
replacement in adequate doses will largely prevent these
complications provided the treatment is started before
signiﬁcant damage to the lungs has been sustained.
Opportunistic infections. Pneumonia due to Pneumocystis
jiroveci (PCP) is a presenting feature of this syndrome in
around 40% of cases (Levy et al, 1997; Winkelstein et al, 2003).
In the presence of normal T lymphocyte counts and a negative
human immunodeﬁciency virus test, this will be the most
likely underlying diagnosis in male infants presenting with
PCP. Chronic cryptosporidial infection is another common
infection in these patients. Symptomatic chronic intestinal
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weight loss with persistent diarrhoea. Molecular studies
for cryptosporidium infection, involving polymerase chain
reaction amplication of parasite DNA in patients with
CD40 ligand deﬁciency suggest that subclinical infection is
common and in many cases the organism is not detectable by
stool microscopy, but only by molecular testing (McLauchlin
et al, 2003).
Cholangiopathy, with the organism found in the biliary
tree, is a common complication of both clinical and
subclinical infection. It can result in disturbed liver function
tests typically with raised gamma glutamyl transferase levels
and, over a period of time, the development of sclerosing
cholangitis potentially leading to cirrhosis with a risk of
cholangiocarcinoma (Hayward et al, 1997; Rodrigues et al,
2004). In early series not treated with bone marrow
transplantation, chronic liver disease was a feature in 50%
of affected individuals and was responsible for early death in
many cases (Levy et al, 1997). Liver transplantation has been
attempted, but with poor results and recurrence of the disease
in the transplanted liver. A single successful case of combined
liver and bone marrow transplant action has been reported
(Hadzic et al, 2000). The handling of certain other pathogens
requires similar mechanisms to that for cryptosporidium
(Subauste et al, 1999). Cerebral toxoplasmosis (Leiva et al,
1998; Yong et al, 2008a) and cryptococcosis (Simon et al,
2005) have been described. Cotrimoxazole has been shown to
have some beneﬁcial effect in the prevention of toxoplasma
infection in immunocompromised individuals but is not
completely efﬁcacious (Bucher et al, 1997; Weigel et al, 1997;
de Medeiros et al, 2001).
Though CD40/CD40 ligand interaction is thought to be
important in the handling of mycobacteria, in practice,
tuberculosis is relatively uncommon, being reported in only
one case in the two large series (Levy et al, 1997; Winkelstein
et al, 2003) and in occasional other case reports (Shah, 2005).
Histoplasmosis was reported in one case in the North
American series (Winkelstein et al, 2003). Disseminated atyp-
ical mycobacterial or Bacillus Calmette-Gue ´rin (BCG) infec-
tion has not been reported in patients with CD40 ligand
deﬁciency. However, atypical mycobacterial disease is a
relatively common manifestation in defects of NF jB signalling
(Dai et al, 2004). This may reﬂect deﬁciencies of signalling
pathways other than through CD40.
Handling of cytomegalovirus (CMV) infection can be
problematic in these patients (Levy et al, 1997; Winkelstein
et al, 2003) and disseminated infection can be seen as an initial
presenting illness (Benesch et al, 2000). CMV has also been
implicated in some cases of chronic sclerosing cholangitis
(Hayward et al, 1997). Human Parvovirus infection was
described in three cases with leaky splice mutations resulting
in partial molecular expression and therefore late presentation
of the disorder. In all cases there was a chronic anaemia, which
resolved upon commencement of immunoglobulin therapy
(Seyama et al, 1998b).
Neutropenia. Neutropenia is a common complication in boys
with CD40 Ligand deﬁciency. In one series it was reported as
occurring at some stage in 50% of cases (Levy et al, 1997). The
clinical course of the neutropenia may be transient or it may be
prolonged and persistent. The precise mechanism by which
this occurs is not well understood. Anti-neutrophil antibodies
cannot be detected. Early myeloid progenitors express CD40
and ligation has been shown to stimulate myelopoeisis,
suggesting that lack of a CD40-mediated stimulation of
precursors may play a role (Atkinson et al, 1998; Brown
et al, 1998; Solanilla et al, 2000).
Early reports suggested that treatment with high doses of
immunoglobulin helped resolve the neutropenia (Banatvala
et al, 1994) but in the wider European experience the problem
only responded to this treatment in around half the cases (Levy
et al, 1997). The neutropenia is usually responsive to granu-
locyte colony-stimulating factor.
Autoimmunity. Autoimmune complications are relatively
common in patients with defects of CD40 signalling. Mature
naı ¨ve B-cells from CD40 ligand-deﬁcient patients were shown
to express a high proportion of auto-reactive antibodies
suggesting a role for CD40 ligand/CD40 interaction in
mediating peripheral B-cell tolerance (Herve et al, 2007). In
the Levy study, seronegative arthritis affected 11% and
inﬂammatory bowel disease affected 6% of cases while there
were three patients with thrombocytopaenia and one with
autoimmune haemolytic anaemia. A small number of cases
were also shown to have a variety of autoantibodies though not
associated with disease at the time (Levy et al, 1997). In the
North American series, 12 of 79 (15%) of patients had anaemia.
Three of these were due to parvovirus infection. Some of the
remainder may have been autoimmune in nature though
insufﬁcient detail was reported to be sure (Winkelstein et al,
2003). Other occasional cases of autoimmune disease have been
reported in CD40 ligand deﬁciency (Schuster et al, 2005).
Autoimmune/inﬂammatory disease is also a feature in those
patients with defective NF jB signalling presenting with a
Crohns-like inﬂammatory colitis (Orange et al, 2005).
Malignancy. Boys with CD40 ligand deﬁciency suffer an excess
risk of malignant disease affecting the biliary tree (Hayward
et al, 1997; Levy et al, 1997) and intestine, including
neuroendocrine tumours (Zirkin et al, 1996; Malhotra & Li,
2008). An excess risk of lymphoid malignancy has not been
reported.
Management
Immunoglobulin replacement therapy should be initiated on
diagnosis and will largely correct the clinical consequences of
humoral immunodeﬁciency. The susceptibility to opportunis-
tic infections is more problematic. Prophylaxis against pneu-
mocystis should be commenced and consideration given to
approaches to correct the underlying disorder.
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et al, 1995) is a theoretical possibility for corrective therapy but
the potential clinical problems associated with unregulated
ligation of CD40, not only on immunological cells but also on
other cell lineages, mitigates strongly against this approach.
The mainstay of corrective therapy is bone marrow
transplantation and this has been successfully employed to
treat all three of these conditions. The largest reported series
of bone marrow transplantation for CD40 ligand deﬁciency
(Gennery et al, 2004) looked at 38 patients from eight
European countries. These included a mixture of patients
with and without organ damaging complications including
liver disease and bronchiectasis. Twenty-six (68%) of the
patients survived but four (10%) had autologous reconstitu-
tion, one of whom achieved full engraftment after a second
procedure. Two of the four with autologous reconstitution
had received full and two reduced intensity conditioning
(RIC). One patient had extremely poor immunological
reconstitution despite achieving full donor engraftment.
Overall, a cure was achieved in 22 (58%). Though the cure
rate was better in those without liver disease (72%), absence of
pre-existing liver disease was not a signiﬁcant predictor of
survival. The presence of lung disease and the use of a
mismatched unrelated donor did correlate with a poorer
chance of survival. Fully matched unrelated donors did as well
as matched sibling donors. RIC regimens were used in too few
patients in the survey to draw any conclusions about its
usefulness. Other studies have used RIC to good effect but
only in small numbers (Kikuta et al, 2006). RIC may improve
the outcome but carries the risk of rejection, which was not
insigniﬁcant in the larger survey. Infection was a major factor
in all 12 fatal cases (32%). In 6 this was caused by
cryptosporidium. There was no association between transplant
variables, such as donor type or conditioning used, and the
occurrence of cryposporidial infection. Another report indi-
cates that cryptosporidial infection can reactivate after BMT
even when apparently subclinical and with negative stools on
conventional testing (McLauchlin et al, 2003). In the same
report it was shown that, despite the fact that antimicrobial
treatment for cryptosporidium is poorly efﬁcacious, some
patients with cryptosporidial reactivation after transplantation
can control the infection and survive. In survivors who had
pre-existing liver disease, there is resolution of symptoms and
normalization of abnormal liver function tests (authors’
unpublished observations and Dimicoli et al (2003).
Given the potential problems with stem cell transplantation,
an alternative approach for boys with CD40 ligand deﬁciency
is to adopt a waiting brief; treating with immunoglobulin and
cotrimoxazole and monitoring closely for complications such
as liver disease and neutropenia. In this approach, transplan-
tation is only performed at the ﬁrst sign of problems. This is
particularly relevant if a fully matched donor cannot be found
or if the patient has a hypomorphic mutation. Some boys with
the condition will remain well and thrive for a number of years
on this regimen (authors’ unpublished observations) Careful
attention to avoidance of cryptosporidium exposure is impor-
tant. The advice given to patients is shown in Table II.
The numbers of patients transplanted for CD40 deﬁciency
and NF jB signalling defects are too small to derive ﬁrm
conclusionsaboutthisapproachinthesedisorders.Casereports
describing successful outcomes are described for both (Dupuis-
Girod et al, 2006; Mazzolari et al, 2007; Tono et al, 2007). A
recent review suggested that in transplantation for NFjB
signalling defects, achieving good levels of engraftment may be
difﬁcult(Fishet al,2009)whileinanotherreporttransplantation
corrected the immunodeﬁciency but failed to correct the colitis
(Pai et al, 2008).
Gene therapy for CD40 ligand deﬁciency is under develop-
ment. However, experiments on CD40 ligand knockout mice
show that introduction of CD40LG, resulting in constitutive
expression of this molecule, caused lymphoproliferative disease
in the majority of mice treated that was unrelated to potential
insertional mutagenesis (Brown et al, 1998; Sacco et al, 2000).
This indicates that tight control of the expression of this
molecule is essential. As a result strategies for developing gene
therapy for this condition will need to employ transduction
not only of the structural gene but also the elements for
regulating its expression, or possibly use methods utilizing
DNA or RNA repair (Tahara et al, 2004).
Forms of HIGM syndrome associated with a pure
humoral immune defect
Intrinsic B cell defects in the mechanism of CSR result in
HIGM syndrome with a pure humoral immunodeﬁciency
without susceptibility to opportunistic infections.
Activation induce cytidine deaminase (AID) deﬁciency
HIGM
This was the second recognized genetic cause of HIGM
syndrome and the ﬁrst autosomal recessive variety (Revy et al,
2000). It is much rarer than CD40 ligand deﬁciency. AID is
expressed transiently and selectively in germinal centre B-cells
following stimulation through CD40 and cytokines. It is
responsible for deaminating cytidine into uracil residues in the
early phase of CSR and SHM. In most cases mutations in the
AID gene (AICDA) cause HIGM syndrome in an autosomal
recessive manner. In the largest reported study, 15 different
mutations were reported in 29 patients with no evidence of a
Table II. Reducing the risk of cryptosporidium infection.
All drinking water to be boiled or ﬁltered through a professionally
ﬁtted ﬁlter with <1 lm pore size
Avoid toddler swimming pools and swimming in ponds and lakes
Swimming is allowed in pools from an age >5 years
Avoid contact with farm animals (especially lambs and calves)
Minimize contact with kittens and puppies
Investigate the cause of all diarrhoeal episodes
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2004). Other reports suggest there may be some genotype/
phenotype correlation in that patients with mutations in the
C terminal part of the gene have impaired CSR but not SHM
(Ta et al, 2003) and patients with a speciﬁc heterozygous
mutation in the C terminal end of the molecule exhibit a
similar phenotype with autosomal dominant inheritance – see
below. In other studies a few commonly occurring mutations
were found (Minegishi et al, 2000; Zhu et al, 2003). In typical
AID defects, both CSR and SHM are defective. IgM levels are
normal or high while absent or very low levels of IgG, IgA and
IgE are seen. Memory B cells expressing CD27 are present in
normal numbers.
AID C terminal defect
An autosomal dominant form of AID deﬁciency has been
described as caused by a missense mutation in the C terminal
domain of the molecule, which is the domain involved in
nuclear egress. Studies on these patients showed that there was
defective CSR but not SHM, suggesting that the C terminal
part of the molecule is involved with the enzyme complexes
involved in DNA repair in CSR but not repair after SHM
which uses different mechanisms (Imai et al, 2005).
Uracil N glycosylase (UNG) deﬁciency
Deﬁciency of this enzyme has been described as another cause
of HIGM syndrome in a small number of patients (Imai et al,
2003a). Patients suffer a similar clinical picture to AID
deﬁciency. CSR but not SHM is impaired in this disorder
although there is marked skewing of the bases involved in
SHM towards G–C rather than A-T. Numbers of cases
reported are too small to draw ﬁrm conclusions about the
clinical phenotype but frequent bacterial infections and
lymphoid hypertrophy seem to occur.
PMS2 deﬁciency
PMS2 (postmeiotic segregation increased 2) is one of the
proteins involved in the complex mediating mismatch repair
of DNA. Along with other members of the mismatch repair
enzyme complex, mutations in PMS2 have been identiﬁed
as being associated with gastrointestinal adenocarcinomas
(Gologan & Sepulveda, 2005). A recent report described the
presence of mutations in PMS2 in three patients with a defect
in DNA cleavage as part of a CSR defect (Peron et al, 2008).
There was a partial immunological phenotype of HIGM with
low (but not absent) IgG associated with complete IgA
deﬁciency in one patient and a low IgA in one other which
corrected over time. CSR was markedly abnormal in vitro.
There was either no defect or only a mild defect of SHM. The
patient with the most severe immunophenotype was reported
as having severe bacterial infections prior to diagnosis and
subsequently developed colonic adenocarcinoma.
Other undeﬁned forms of HIGM syndrome due to defects
of CSR mechanism
Not all cases of HIGM syndrome can be ascribed to known
genetic defects. The characteristics of two defects of CSR both
inherited in an autosomal recessive fashion but for which no
genetic cause has yet been identiﬁed have been reported. In the
ﬁrst (Imai et al, 2003b) a B cell defect affecting CSR
downstream of DNA transcription step was found without
radiosensitivity. SHM was not affected. A possible cofactor for
AID function has been postulated. A second form of CSR
abnormality reported in 16 patients was associated with
radiosensitivity implying a defect in dsDNA repair mecha-
nisms (Peron et al, 2007). Durandy (2009) recently reported
an update on these defects.
Clinical complications
Other than AID deﬁciency, very small numbers of cases have
been reported on which to base a description of clinical
features. Some of the defects, such as PMS2, may result in a
partial phenotype as far as immunological ﬁndings are
concerned though clinical features are not fully described.
The main potential clinical complications are described below.
Infections. In AID deﬁciency, two case series have been
reported (Minegishi et al, 2000; Quartier et al, 2004). Prior
to commencing treatment with immunoglobulin, recurrent
severe infections mainly bacterial and most often causing
pneumonia were seen. Other sites of infection were the skin,
lymph nodes, gastrointestinal tract and central nervous system,
the last including bacterial meningitis and one case of Herpes
simplex encephalitis. The onset of infections was early, usually
before 2 years of age, but in the study reported by Minegishi
et al (2000) a considerable delay often occurred before a
diagnosis of immunodeﬁciency was made. Opportunistic
infections were not described. The numbers of cases reported
with disorders other than AID deﬁciency is too small to draw
ﬁrm conclusions but the clinical susceptibility to bacterial
infections seems to be similar.
Lymphoid hypertrophy. Marked lymphoid hypertrophy is a
clinical feature of AID deﬁciency that is reported in one half to
two-thirds of cases (Minegishi et al, 2000; Quartier et al,
2004). It has also been described in the other forms of CSR
defect (Durandy et al, 2006). It can affect all lymphoid tissues
but peripheral lymphadenopathy and tonsillar hypertrophy
were most commonly reported. Splenomegaly was relatively
uncommon, being reported in 2 of 29 in one series (Quartier
et al, 2004). Lymph node and tonsillar histology
characteristically shows giant germinal centres (Revy et al,
2000). The driver for such germinal centre hypertrophy is not
clear. Interestingly, treatment with immunoglobulin seems to
reduce the likelihood of developing this complication with
only two of 29 patients developing this complication after
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knock out mice, Peyer’s patch hypertrophy has been shown to
be driven by intestinal bacterial overgrowth (Fagarasan et al,
2002).
Autoimmunity. In both reported series of AID-deﬁcient
HIGM syndrome, autoimmune complications were described
with an incidence of around 20% and included immune
cytopenias, arthritis and hepatitis (Minegishi et al, 2000;
Quartier et al, 2004). Potential mechanisms for the
autoimmune process have been reviewed (Jesus et al, 2008).
It has also been postulated that the B cell lymphoproliferation
characteristic of the condition leads to the development of
ectopic lymphoid tissue in non lymphoid organs, predisposing
to organ speciﬁc autoimmunity (Hase et al, 2008).
Autoimmune complications would also be expected to occur
in UNG-deﬁcient forms of the disorder.
Malignancy. To date, despite the tendency to lymphoid
hyperplasia in AID deﬁcient patients, malignant
lymphoproliferation has not been described. There is a
probable predisposition to B cell malignancy in UNG
deﬁciency although this has not been reported in the few
cases described (Durandy et al, 2006). UNG knock out mice
are prone to B cell lymphomas consistent with a role for the
base excision function of this enzyme in correcting mutagenic
inﬂuences (Nilsen et al, 2003).
Management
The mainstay of treatment for these forms of HIGM syndrome
is immunoglobulin replacement therapy. This is reported as
reducing markedly the incidence of bacterial infections and
also reducing the likelihood of developing lymphoid hyper-
trophy (Quartier et al, 2004). Early diagnosis and initiation of
treatment is important in reducing the likelihood of the
patient developing bronchiectasis and/or chronic sinusitis.
Studies of immunoglobulin-deﬁcient patients generally have
found that these complications are usually established before
initiation of replacement therapy and may then progress
despite treatment (Wood et al, 2007). Subcutaneous treatment
with immunoglobulin has been shown to be both efﬁcacious
and acceptable to antibody-deﬁcient patients (Chapel et al,
2000).
Autoimmune complications are generally managed along
the lines used in non-immunodeﬁcient patients. The authors
are not aware of any reports of usage of anti CD20 monoclonal
antibody (rituximab) in these disorders.
Corrective therapy, such as bone marrow transplantation,
cannot generally be justiﬁed given the fact that these are pure
humoral deﬁciencies showing good response to immuno-
globulin therapy. Theoretically, such an approach might be
justiﬁed in patients with uncontrollable autoimmune mani-
festations or in those who have developed lymphoid
malignancies.
Forms of HIGM syndromes associated with
syndromes affecting DNA repair
Ataxia- telangiectasia (A-T) and Nijmegen Breakage syndrome
involving defects in ATM and NBS1, respectively, are both
conditions in which immunodeﬁciency can be a prominent
feature (Taalman et al, 1989; Staples et al, 2008). These
enzymes are closely involved in CSR (Reina-San-Martin et al,
2004; Kracker et al, 2005). ATM deﬁciency does not affect
SHM while NBS1 does (Pan-Hammarstrom et al, 2003).
Clinically, a number of A-T patients have been described as
presenting with a classical HIGM pattern of immunoglobulin
deﬁciency (Etzioni et al, 2007; Soresina et al, 2008; Noordzij
et al, 2009). More commonly there is IgA and/or IgG2
deﬁciency. Since the IGH heavy chain genes for these two
isotypes are amongst the furthest downstream from the VDJ
genes it has been postulated that the defective CSR function in
A-T is more marked for rearrangements involving longer
intervening DNA sequences (Giovannetti et al, 2002). In both
conditions chromosomal translocations, particularly affecting
the immunoglobulin and T cell receptor genes on chromo-
somes 7 and 14, are commonly found. Lymphomas are
common in both conditions. In A-T these are more often of T
rather than B cell origin. Ataxia-telangiectasia-like disorder
(ATLD) is caused by mutations in the MRE11A gene, also
involved in CSR and SHM. Though defective CSR has been
shown, clinical or laboratory evidence for immunodeﬁciency is
usually not present (Delia et al, 2004; Taylor et al, 2004; Fernet
et al, 2005).
HIGM as part of other primary antibody
deﬁciency disorders
Preserved levels of IgM may be found at presentation in
patients presenting with antibody deﬁciency syndromes not
due to any of the classical HIGM disorders. This includes
X-linked agammaglobulinaemia caused by mutations in
Bruton tyrosine kinase (BTK). In a series including 140
patients with a HIGM picture, BTK mutations were found in
three patients (Lee et al, 2005). In the same study, 33
patients without an identiﬁable genetic defect were thought
to include patients with CVID. This disorder is often part of
the differential diagnosis in patients with a HIGM as
preservation of IgM production is not unusual, at least in
the early stages of CVID. Sometimes a frank HIGM picture is
seen. Causes of CVID have recently been reviewed (Yong
et al, 2008b). A number of genetic defects have been
described, which may account for around 10% of cases,
with genetic lesions still to be identiﬁed in the remainder.
Mutations in genes encoding TACI (TNFRSF13B), ICOS
(ICOS), CD19 (CD19), and, most recently, B cell activating
factor receptor (BAFF-R; TNFRSF13C) (Warnatz et al, 2009)
all involved in the process of B cell activation, have been
described in CVID. It can be postulated that failure of signals
through these receptors could affect the antigen-dependent
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take place. Recently, variant sequences in MSH5, one of the
complex of mismatch repair enzymes involved in CSR and
SHM have been shown to be associated with some cases of
CVID and IgA deﬁciency (Sekine et al, 2007). This ﬁnding
suggests that defects in the mechanisms of CSR (and thus
true HIGM disorders) may account for a proportion of
genetically undeﬁned cases labelled as having CVID.
Conclusion
Studies on patients with HIGM syndrome can now identify the
genetic cause in around 75–80% of cases. The remainder is
currently undiagnosed at the genetic level. Treatment options
depend on the type of defect with those involving defective
CD40 signalling requiring consideration of corrective therapy
whilst those with intrinsic B cell defects mostly require
immunoglobulin replacement therapy alone.
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